NASDAQ: RGLS - Regulus Therapeutics Inc.

Yield per half year: +10.19%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Regulus Therapeutics Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Regulus Therapeutics Inc.

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.

more details
The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2012-10-04
ISIN US75915K3095
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.regulusrx.com
Цена ао 1.29
Change price per day: +15.33% (1.5)
Change price per week: +26.28% (1.37)
Change price per month: +27.21% (1.36)
Change price per 3 month: +12.34% (1.54)
Change price per half year: +10.19% (1.57)
Change price per year: -39.93% (2.88)
Change price per 3 year: +499.45% (0.2886)
Change price per 5 year: +135.41% (0.7349)
Change price per year to date: +13.07% (1.53)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 1.29 9
P/E 0 0
EV/EBITDA -0.1331 0
Total: 3.63

Efficiency

Title Value Grade
ROA, % -80.67 0
ROE, % -95 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0089 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % -86.11 0
Yield Ebitda, % 83.82 9
Yield EPS, % -83.76 0
Total: 5.8
More

Institutions Volume Share, %
Federated Hermes, Inc. 3875578 5.92
FMR, LLC 2922600 4.46
NEA Management Company, LLC 1945579 2.97
DAFNA Capital Management, LLC 1111049 1.7
Vanguard Group Inc 286431 0.44
Victory Capital Management Inc. 271736 0.42
Sarissa Capital Management, LP 185183 0.28
Exome Asset Management LLC 178404 0.27
Geode Capital Management, LLC 122521 0.19
Renaissance Technologies, LLC 54600 0.08

ETFShare, %Profitability for 1 year, %Dividends, %
iShares Micro-Cap ETF 0.02905 17.09 1.54048
Avantis U.S Small Cap Equity ETF 0.00491 27.77 1.68271
ProShares UltraPro Russell2000 0.00248 89.82 1.47873
ProShares Hedge Replication ETF 0.00063 5.92 1.47892
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 3000 ETF 0 31.87 1.43817
Vanguard Russell 2000 Growth ETF 0 23.05 0.60264
030.381.39



Head Job title Payment Year of birth
Mr. Joseph P. Hagan M.B.A. CEO & Director 958.23k 1969 (56 years)
Ms. Crispina Calsada CPA Chief Financial Officer 579.3k 1970 (55 years)
Mr. Christopher Ray Aker J.D. Senior VP, General Counsel & Corporate Secretary 575.94k 1961 (64 years)
Mr. Daniel J. Penksa VP of Finance & Controller N/A 1986 (39 years)
Dr. Claire Susan Padgett M.S., M.T., Ph.D. Senior Vice President of Clinical Operations N/A
Dr. Rekha Garg M.D., M.S. Chief Medical Officer N/A
Dr. Preston S. Klassen M.D., M.H.S. President, Head of Research & Development and Director N/A 1969 (56 years)
Mr. Edmund Lee Ph.D. Vice President of Translational Medicine N/A

Address: United States, San Diego. CA, 4224 Campus Point Court - open in Google maps, open in Yandex maps
Website: https://www.regulusrx.com